Cinqair® (reslizumab)

Covered only as FDA‑indicated add‑on maintenance therapy for adults (≥18) with severe eosinophilic asthma and excluded for patients who do not meet those criteria (e.g., age <18, blood eosinophils <400 cells/µL, inadequate prior controller therapy, lack of objective uncontrolled asthma, or not prescribed/consulted by a specialist). Key requirements: blood eosinophils ≥400 cells/µL within 4 weeks (or within 4 weeks before prior mAb therapy), ≥3 months of ICS plus another controller, objective evidence of uncontrolled asthma (exacerbations, hospital/ER visits, FEV1 <80% predicted or FEV1/FVC <0.80, or steroid dependence), initial approval 6 months (renewal 12 months) with specialist prescribing/consultation, and reauthorization requires ≥6 months of Cinqair, continued ICS use, and documented clinical response.

"Clinical documentation that asthma was uncontrolled prior to starting Cinqair, including one or more of: number/dates of exacerbations requiring systemic corticosteroids in the previous year; recor..."